| | | 多奈哌齐治疗阿尔茨海默病的临床疗效研究
| | 药学论文下载【摘要】 目的药学论文下载：验证多奈哌齐（Donepezil）治疗阿尔茨海默病(AD)的药学论文下载安全性及有效性。方法：对61例AD患者进行多奈哌齐和他可林（Tacrine）的多中心开放、对照治疗，其中多奈哌齐组33例（5mg/d），他可林组28例（平均100mg/d）；共治疗12周。应用简易精神状态检查（MMSE），日常生活能力量表（ADL）评定临床疗效，用副反应量表（TESS）评定副反应。结果：多奈哌齐组治疗总有效率为69.70%，显效率为51.52%，他可林组分别为67.86%和46.43%，起效时间均在治疗第四周末；两组间差异无显著性（χ2分别=0.023和0.011）。多奈哌齐组和他可林组治疗前后MMSE评分及加分率，ADL评分及减分率的差异均无显著性（P>0.05）。多奈哌齐组的不良反应较他可林组显著少而轻，仅有6例病人存在轻度的恶心或胃纳减退。结论：多奈哌齐能有效治疗AD，且不良反应少而轻微。
【关键词】 阿尔茨海默病；多奈哌齐；他可林
A comparative study of donepezil and Alzheimer disease for Clinical research
【abstract】 Objective Verify that the Donepezil of many what Pains cures safe nature and effectiveness that Ah you Alzheimer disease ( AD ) .Methods But having more what the many centers open of neat and he forest ( Tacrine ) of Pay and contrast to 61 example AD patients is cured , among them many what I Zoos Pay 33 examples ( 5mg/d ) , but his Lin Zu of 28 examples ( average 100mg/d ) We should cure 12 weeks altogether . Applying the simple and easy state of mind check ( MMSE ) , the day-to-day viability scalogram ( ADL ) is passd judgment on the clinical curative effect , with the by-reaction scalogram ( TESS ) evaluation by-reaction . Results Many what Qi Zu Pai cure that but total availability for 51.52%,shis forest component part not for 67.86% is all curing the around end with 46.43%, rises to imitate time for 69.70%,s produce effects rate The difference does not have the significance (χ2 parts = 0.023 and 0.011 ) between two teams . But many what Qi Zu Pai and his Lin Zu MMSE around curing gives a mark and adds the divides rate, and ADL gives a mark to be reached difference that subtracts the divide rate all not to have the significance (P>0.05). But his Lin Zu is seldom notable and light to the many what
bad reactions of I Zu Pay, and the nauseating or stomach that only has 6 example patients gently to exist to spend is received to drop.Conclusions donepezilis an effective Treatment Medicine Alzheimer disease, with less side effects and better safety compared with tacrine.
【Key words】 Alzheimer disease; Donepezil; tacrine
盐酸多奈哌齐是90年代末相继获得美国FDA和英国MCA批准上市的第二代具有高度选择性，长效的，可逆的乙酰胆硷酯酶抑制剂（CI）[1]。国外的开放和对照研究结果显示，多奈哌齐是当前最为实用的AD对症治疗用药[1～8]，为进一步验证多奈哌齐对中国AD患者的临床疗效及其安全性，由湖北省四家医院的神经、精神科医师组成“多奈哌齐”治疗协作组，进行了为期12周的多中心开放、对照治疗，对药物的有效性及安全性进行了评估。
对象和方法
一、对象
1、入组标准：
入组对象须为作者单位的住院及门诊AD患者，性别不限，年龄≥50岁（女性患者须
符合停经2年或已作过外科绝育手术的条件），总体身体健康状况能走动或在拐杖的协助下
|
| | |
| | | | <<<<<全文未完>>>>> 全文字数约3800字 | |
| | |
| |
|
教育论文中心